Ladies and gentlemen, good day. Welcome to the Medanta Global Health Q1 FY 2027 Earnings Conference Call hosted by JM Financial Institutional Securities. As a reminder, all participant lines will be in the listen-only mode, there will be an opportunity for you to ask questions after the presentation concludes. Should you need assistance during this conference call, please signal an operator by pressing star then zero on your touchtone phone. Please note that this conference is being recorded. I now hand the conference over to Mr. Amey Chalke from JM Financial Institutional Securities. Thank you, over to you, sir. Thank you, Albert. Good afternoon, warm welcome to all the participants on Global Health Limited Q1 FY 2027 earnings call hosted by JM Financial. Today on this call, we have with us from the management, Dr. Naresh Trehan, Chairman and Managing Director, Mr. Pankaj Sahni, Group CEO and Director, Mr. Yogesh Kumar Gupta, Chief Financial Officer, Mr. Gaurav Chugh, Head of Investor Relations. I will now hand over the call to Dr. Trehan for his opening remarks. Thank you, over to you, doctor. Thank you for this opportunity. Good afternoon to all of you. Thank you for joining us today on Medanta's Q1 FY 2027 earnings conference call. I hope you all have had the chance to review the results presentations that was released yesterday. At Medanta, we continue to build on our vision of delivering world-class, patient-centric, compassionate care. Clinical excellence remains the cornerstone of our identity, during the quarter, we remained focused on strengthening that foundation through consistent and disciplined execution. The quarter has been encouraging from both a clinical operational standpoint. Our network continued to witness healthy growth in patient volumes, driven by increasing demand across key specialties, higher case complexity, sustained trust from patients referring physicians. We also continue to strengthen our position as a destination to complex care through investments in advanced technologies, multidisciplinary programs, world-class clinical talent. I would like to highlight that our Medanta Lucknow has done over 1,000 joint replacements using the latest robotic technology, That comes on top of thousands of robotic surgeries that we have executed across the system in every specialty, including the more complex cardiac other specialties. Talent remains core to our delivery model. During the quarter, we onboarded over 70 doctors, including 50-plus senior clinicians across specialties. This strengthens our medical depth enhances our ability to manage complex multidisciplinary care. As we grow, we remain focused not just on scale, but on creating meaningful, measurable impact by enhancing access to advanced healthcare, nurturing clinical leadership, continuing to lead through innovation. Based on this philosophy, we have scaled up our plans for Guwahati, which will now have 650-bed super specialty hospital. Our objective is to improve access to advanced tertiary and quaternary healthcare for patients across the northeast, where significant demand currently travels outside the region for complex treatment. With a resilient business model, deep medical expertise, and a purpose-driven culture, we believe we have the right building blocks in place to carry this momentum forward. To touch more lives, serve more communities, and set new benchmarks in quality care. Overall, we are pleased with the progress during the quarter and remain confident in our long-term growth strategy. With that, let me now hand over the call to Mr. Pankaj Sahni, our Group CEO, who will walk you through the strategic, operational, and financial highlights for the quarter. Thank you all of you for your participation. Over to you, Pankaj. Thank you, Dr. Trehan. Good afternoon, and thank you for joining us today. FY 2027 has begun on a strong note for Medanta. In quarter one FY 2027, we delivered robust growth in our total income and EBITDA, reflecting the strength of our operating platform and disciplined execution across the network. The growth was broad-based, driven by robust patient volumes, improved realizations, continued scaling of Medanta Noida, and sustained momentum across our established hospitals. Let me first take you through our financial performance highlights for Q1 FY 2027. Consolidated income for the quarter was INR 13,262 million, representing a healthy growth of 26% year-on-year. EBITDA, excluding Noida, witnessed a growth of 24% year-on-year to INR 3,201 million, with margins improving to 25.8%, highlighting the continued strength of our core operating portfolio. Reported EBITDA, including Noida, stood at INR. 3,153 million, registering a healthy 23% year-on-year growth with EBITDA margins of 23.8%. Below EBITDA, the year-on-year comparison also reflects higher depreciation and finance costs associated with our expanded asset base, particularly following the commissioning and ramping up of Noida. Profit after tax was INR 1,573 million compared to INR 1,590 million in Q1 FY 2026. As highlighted in our results, the year-on-year profit after tax was impacted by a non-recurring exceptional income of INR 196 million recognized in Q1 FY 2026 relating to the reversal of potential interest liability on EPCG subsequent to the successful merger of our 100% subsidiary MHPL with GHL. Excluding this one-time item, our underlying earning trajectory continues to remain very healthy. Operationally, we continue to witness robust momentum across the network. Inpatient volumes increased by 28% year-on-year, while outpatient volumes grew by 34%, reflecting sustained demand across our specialties and the continued scale-up of our new facilities. Occupied bed days for the quarter increased by 21%, with network occupancy remaining healthy at 63% on expanded bed capacity. Excluding Noida, occupancy across the network stood at approximately 66%, demonstrating the robust utilization levels across our existing hospitals. Average revenue per occupied bed, or ARPOB, grew by 5% year-on-year to INR 70,244, supported by favorable case mix, increasing contribution from high acuity specialties, and improvement in operational efficiency. International patient revenue witnessed a growth of 23% year-on-year to INR 782 million, reflecting strong growth despite current geopolitical tensions. Our OPD pharmacy business also continued its strong growth trajectory, with revenue increasing 51% year-on-year to INR 609 million, supported by both hospital pharmacies and our expanding retail pharmacy network. During the quarter, we operationalized 72 additional beds, including 51 beds at Noida and 21 beds at Lucknow, taking our operational bed capacity to 7,337. Medanta Noida. Let me now provide you with an update on Medanta Noida, the newest asset in our portfolio. When we formally inaugurated in November 2025, we had indicated that a facility of this scale would require some gestation period before achieving operating breakeven. We are very satisfied with the progress of Medanta Noida over the last two quarters. In Q1 FY 2027, we have witnessed a strong ramp-up across all categories of patients and have concluded major empanelments and contracts across insurance, PSU, and other corporates. In this quarter, Noida has seen a significant reduction in its EBITDA losses. On the financial performance, Noida generated total income of INR 855 million compared to INR 525 million in Q4 FY 2026. More importantly, the EBITDA loss declined sharply from INR 236 million in Q4 FY 2026 to only INR 49 million in Q1 FY 2027. During the quarter, we further expanded our operational capacity with the addition of 51 beds while continuing to strengthen our consultant base and specialty offerings. Based on the current operating trajectory, we expect Noida to achieve EBITDA breakeven earlier than our previous expectations. While we remain focused on achieving profitability, our larger objective continues to be building another flagship Medanta institution which- Ladies and gentlemen, the line for the management has dropped. Please stay connected while I get them reconnected. Thank you. Ladies and gentlemen, the line for the management has been reconnected. Please go ahead, sir. Hi. My apologies for that technical delay. Let me just reread out some of our performance with respect to Noida. On the financial performance, Noida generated total income of INR 855 million compared to INR 525 million in Q4 FY 2026. More importantly, the EBITDA loss declined sharply from INR 236 million in Q4 FY 2026 to only INR 49 million in Q1 FY 2027. During the quarter, we further expanded our operational capacity with the addition of 51 beds, while continuing to strengthen our consultant base and specialty offerings. Based on the current operating trajectory, we expect Noida to break even on an EBITDA basis earlier than our previous expectations. While we remain focused on achieving profitability, our larger objectives continues to be building another flagship Medanta institution with strong clinical capabilities, sustainable market leadership and long-term value creation. As our network continues to expand, we are also enhancing the quality and transparency of our disclosures. Beginning this quarter, we have introduced average revenue per patient, or ARPP, as an additional operating metric. Unlike ARPOBs, which measures revenue generated per occupied bed day, ARPP provides a perspective on revenue generation relative to inpatient volumes. For Q1 FY 2027, ARPP stood at INR 201,891, broadly similar to the number achieved in the corresponding period last year, reflecting stable realization despite the continued ramp-up of newer and existing facilities. Another change we have made this quarter relates to our hospital cluster reporting. Going forward, what were previously referred to as mature hospitals will now be reported as Cluster 1. Similarly, our earlier developing hospitals will now be referred to as Cluster 2, though the composition of hospitals remains the same in Cluster 1 and Cluster 2. Let me first talk about Cluster 1, which comprises our established hospitals at Gurugram, Indore, and Ranchi. Revenue from Cluster 1 stood at INR 7,715 million, registering a year-on-year growth of 10%. The EBITDA stood at INR 1,858 million, reflecting a strong growth of 13% year-on-year with improved margins of 24.1% compared to 23.4% in the corresponding quarter. The performance was supported by a 14% increase in inpatient volumes, reflecting continuous demand. At the same time, ARPOB witnessed a growth of 7%, driven by a favorable specialty mix and improved realizations. Average length of stay improved to 2.8 days while occupancy remained stable at 63%, demonstrating our continued focus on improving operational efficiency without compromising the patient care. ARPP of Cluster 1 stood at INR 290,623 in Q1 FY 2027, almost similar to the previous corresponding quarter. Turning to Cluster 2, comprising Lucknow, Patna, and Noida. This cluster continues to be our growth engine. Including Noida, total income grew by 55% year-on-year to INR 4,983 million, while EBITDA grew by 35% to INR 1,272 million. As Noida is still in its ramp-up phase, we have also provided performance excluding Noida to enable better comparability. On this basis, excluding Noida, Cluster 2 delivered 28% revenue growth and 40% EBITDA growth with a strong EBITDA margin of 32%, highlighting the robust underlying performance of both Lucknow and Patna. Overall, the Cluster 2 hospitals witnessed a 50% increase in inpatient volumes while occupied bed days increased by 44%, reflecting continued capacity utilization across the hospitals. ARPOB grew by a strong 9% to INR 61,742, supported by favorable case mix and improved realization across the network. ARPP of Cluster 2 stood at INR 182,407 in Q1 FY 2027, up 5% compared to the previous corresponding quarter. Occupancy for Cluster 2 stood at 62% compared to 64% in the same quarter last year, marginally lower due to the phased commissioning and capacity addition at Noida. Overall, we remain encouraged by the performance of Cluster 2. Lucknow and Patna continue to deliver strong operating performance while Noida is ramping up significantly. Together, these hospitals provide a strong platform for Medanta's next phase of growth. Now coming to our projects. A total of 72 beds were added during the quarter, 51 in Noida and 21 beds additional in Lucknow. We have also revised the scale of our proposed Guwahati hospital. Following the revised building bylaws and National Building Code 2026, the project has now been expanded to a 650-bed super specialty hospital with an estimated project cost of approximately INR 9,700 million. Our announced projects continue to progress through their respective developmental and approval stages. Construction is underway at South Delhi while design, statutory approvals, and planning activities are progressing on the other locations. Together, our announced expansion pipeline now represents nearly 3,350 additional beds, providing a strong runway for sustainable long-term growth. Supported by our strong brand, differentiated clinical capabilities, robust balance sheet, and disciplined execution, we remain confident in our ability to deliver sustainable growth while creating long-term value for our shareholders. With that, I request the operator to open the line for questions. Thank you. Thank you. We will now begin the question and answer session. Anyone who wishes to ask a question may press star and one on their touchtone telephone. If you wish to remove yourself from the question queue, you may press star and two. Participants are requested to use handsets while asking a question. Ladies and gentlemen, we will wait for a moment while the question queue assembles. The first question comes from the line of Sucrit Patil with Eyesight Fintrade. Please go ahead. Good afternoon to the team. My first question, Mr. Pankaj, is, beyond the regular outlook, what are the top two to three execution priorities that you're focusing on in the coming quarters? Alongside that, what do you see as the biggest risk in patient demand shifts or competitive pressures? How are you preparing to manage them while strengthening Medanta's position in multi-specialty hospitals and healthcare services? That's my first question. I have a second question after. Thank you. Our operational and execution priorities don't change on a quarter-to-quarter basis. That's not how we necessarily think about the running of the organization. What I can tell you is that we remain committed to the broad strategies which we have outlined multiple times. The first one, of course, is to ensure that we continue to deliver exceptional clinical and operating performance, which translates to very strong financial performance across all our six hospitals. Most of the hospitals are now in fairly mature stage with even our Patna facility being about 4.5-5 years old in terms of its operations, and the only really new hospital is our Noida facility. As mentioned in the opening comments, we continue to see very strong ramp-up of our Noida facility, of course, that remains an important focus for us. That will continue to add clinical talent, that will continue to scale its beds, continue to improve across all operational and financial parameters, and we have already seen very strong performance on that in Q1. As mentioned in the opening comments, we are a little ahead of our own internal expectations in terms of the financial returns on that particular facility. When it comes to our existing five hospitals, that is Gurgaon, Lucknow, Patna, Ranchi, and Indore. All these facilities, we continue to focus on driving very strong clinical quality. We have been relentless over the course of the last few years in adding in additional clinical capabilities as and where they are needed across the network. That includes both adding in new departments and new specialties. It also includes beefing up the existing specialties with more doctors, and that will remain our priority as we move forward. We have also been investing heavily in technology over the course of the last couple of years, in fact, and we will continue that. That includes addition of equipment like complex LINAC procedures for cancer treatment, newer-end radiation diagnostic capabilities in terms of CT/MR, as well as significant scale-up in robotic procedures and robotic equipment across the network, both in terms of soft tissue as well as orthopedic robots. We will also be adding in some additional capacity with our Indore acquisition of 80 beds coming on board and scaling up cancer services both in Ranchi as well as Indore. On the hospital front, these remain our major priorities. On the retail lab and pharmacy front, we continue to scale as and when the opportunities provide across the markets and areas which we have already laid out. Thank you. My second question to Mr. Gupta is, from a financial point of view, what key risks or challenges do you anticipate in the coming quarters, and what specific measures are being taken to manage margins, cash flow, and balance sheet strength, especially in areas like cost pressures, receivables, or regulatory compliance? Thank you. See, your question about the margins, I think we have seen a good robust margin stable from previous quarters and improving over the years. We have a constant focus on our cost line items, including material cost and the manpower cost as well as other cost items. There is a continuous effort which keeps on going around this. Other question from you, Mayur, was on the cash flows. If you see, our overall cash flows have been strong over previous years, and we see it continuously happening that way only, and we are not seeing any decline in our cash flow generation. The cash flow itself is basically which is going to fund our growth in future through debt and equity from internal accruals. We have a strong balance sheet with a very low leverage add-on today, and we don't see any challenge on that side. Have I missed any other question of yours? No, that's it. Thank you very much for the guidance and best wishes. Yeah. A reminder to all participants, you may press star and one to ask a question. The next question comes from the line of Parth Sodha w ith Trinetra Asset Managers. Please go ahead. Yes, sir. Am I audible? Yes, Parth. Yes. Good afternoon, and thank you for the opportunity. My question is like, as Noida matures, do you believe the consolidated EBITDA margin can move back towards the 2025-2026 range, or will the expansion-related investments keep margins around current levels? We don't give margin guidance as such. If you look at our performance, including the reported EBITDA of Noida, we are already at around 24%, not far off from what you have articulated. This includes about INR 5 crores of losses for the quarter. Obviously, as these losses translate to profits, you will see some amount of expansion and operating leverage. If you look at our margin profile without Noida, we are already at about 26% margin profile without Noida. We don't really see any significant structural reason to have any very significant negative impact on this. The only thing I can say is that there would, of course, be your normal business activities, normal increments, normal cost growth, and all of those kinds of things. We are not seeing any significant change, so we should be benefiting from the operating leverage as Noida matures. There is no very significant additional cost that needs to come in Noida. Okay, got it. Thank you. That's all from my side. Thank you. The next question comes from the line of Abdulkader Puranwala with ICICI Securities. Please go ahead. Hi, sir. Thank you for the opportunity. My first question is with regards to your expansion plan and the CapEx outlay. For the 2,950 beds that you plan to add, how much of that CapEx is already incurred? Let me ask Yogesh to take that. The question is how much CapEx we have already incurred. Yeah. Sorry. In terms of the land parcel or some construction activity which would have picked up out of the INR 4,850 crore. This INR 4,850 crore is the future CapEx which needs to be incurred. Whatever we have done is already part of our balance sheet today. In this quarter, we have done INR 1,610 million of our CapEx. The CapEx plan which we have given in our investor presentation is a future requirement to complete these items, these projects. Okay. Sir, there have been some chatters going around that the government might come out with some revised policy which will expedite the process of setting up hospitals in Tier 2, Tier 3 cities. From our perspective, how do we see the ramp-up then happening at Guwahati and Varanasi? Do you believe that this can expedite the timelines at which you're planning to add these two hospitals? Let me answer this question on two fronts. One, I think that anything which the government announces which helps with the establishment and setting up of hospitals in Tier 2, Tier 3 cities is a very welcome announcement. As you are aware, Medanta has been one of the leaders in going into some of the cities that may have traditionally been considered as Tier 2 or as cities which may not have appealed to be as attractive as part of our larger mission of taking high-quality healthcare to areas where it has not been seen before. With respect to your question around whether this has any impact on Guwahati, I do not believe that there is any real need for any of these policies because we have already most of our approvals in place, and construction activity is already commencing in Guwahati. I do not know what are the policy announcements which you are referencing. As far as our Guwahati build-out is concerned, we are fully on board with our plans for Guwahati. We have already got almost all the approvals we need for construction, and that work is underway. Of course, anything the government comes up with which helps the industry would be welcome. Understood, sir. One final question, if I may. If I look at your specialty contribution mix, oncology, the share has come down from, say, 14.2% last year to 13.5%. Would it be fair to assume that this would be because of the CGHS revision? No. Let me clarify two points. Our share of cancer, what we reported in our investor presentation, has actually increased from 13.7%- 14.4% year on year. When you look at our actual oncology business, it is a little different from maybe how many other people report it. Am I right? Have I got the right numbers? I think you're looking at the FY 2026 number. Sorry. Okay. You're looking at Q1 has gone from 14%- 13.4%- 13.5% Sorry, you're asking Q4 2026 to? Q1 2026- Q1 2027. The share has, on a YOY basis, there has been a 70 basis points kind of a dip, even though when your revenues are growing. Just wanted to know, is there anything to read through those numbers? No. There's nothing to read into these numbers. There are two important points for you to note. One is that we've seen a fairly significant growth in our kidney and urology. You can see that has grown from 7.6% last quarter to about 8.2% this quarter. Our uro cancer, all the urology and kidney cancer work is actually reflected in this department. We don't consider surgical cancer within the cancer specialty. Similarly, if you look at our other specialties, whether it is gastro digestive, we include the GI cancers in that. We include our orthopedic and other cancers in those areas. As such, we have only seen a growth in cancer, no really significant. However, there are some quarterly seasonality, so you do find that in some months you find maybe more of cardiac work, more of gastro work. If you look at our cancer services on a whole. We don't see any significant impact on any of the pricing-related things in terms of the growth on cancer. This is just a sales mix front because the share of one specialty or the other may change. It's a building pie of 100. Other specialties are also growing faster than the cancer. Yeah. So that- And really- That pie, right. Really the right way to look at this is maybe more over an annualized basis because certain quarters, depending on seasonality, like in some quarters, you'll see more of medicine, respiratory versus various diseases. Some quarters you see more of gastroenterology. Over an annual basis is a better way to look at the specialty sales mix. Understood. Thank you. Cancer as a specialty, as we report, is growing. There's no dip in the growth of this specialty as such. Got it. Thank you. All the best. The next question comes from the line of Amey Chalke with JM Financial Institutional Securities. Please go ahead. Yeah. Thank you for giving me the opportunity. I have two questions, both on Noida. The first question, the Noida losses have dropped sharply over this quarter. Is it possible to give some color on the occupancy level and also will there be any fixed cost increase going ahead in Noida for during the year? Sorry, could you just repeat that question, please? Noida performance has improved sharply. Is it possible to give a color on the occupancy of Noida unit at present? I think the current occupancy at Noida is probably hovering somewhere in the 30%-40% range, but that number is actually not really significant or important because of the fact that we continue to add beds. Every few months, if we are adding 30, 40, 50 beds, that occupancy number will fluctuate quite significantly. What I can tell you is that the volume growth in Noida has been quite robust. If you look at our bed growth, it is almost 30%-40%, increasing quarter-on-quarter. I think at this stage to give a stable state occupancy or a current occupancy in Noida is actually a little bit misleading given the way in which that unit is scaling up. Sure. In terms of specialty, all the specialties are operating in Noida at present, or should we see some investment in any of these specialties going ahead? All the specialties are operating with the exception, I would say of so far, we haven't done any liver transplant there. We have done kidney transplant, bone marrow transplant. I am trying to think of any other specialty which is missing. Other than that, I think almost all the major specialties are there. As far as investment goes, most of the specialties which have significant investment like say for example radiation oncology, those have already been added in. I don't think you will see any significant investment. We already have 14 OTs there, radiation oncology latest machine is there, robot is there, O-arm is there. We have all the high-end equipment already there. Sure. Previously you had highlighted in earlier calls that Noida would increasingly take pressure off Gurgaon unit. Is there any coordination or referrals happening between these two units where you are giving referrals from Gurgaon to, let's say, Noida or something, and that has helped Noida to pick up faster? The way in which we operate is that you have hospitals are all working together. It is not a question only of Noida and Gurgaon. We have patients who come from Lucknow to Gurgaon. We have patients who go from Gurgaon to Patna. All of our teams are quite in sync. We do see that there are patients who may not be able to as easily access Gurgaon from a distance point of view. Those patients are finding great amount of comfort in being able to get treated in Noida. In addition to that, several of our department heads in Noida have actually moved from Gurgaon. Our cardiac surgery team, our chest surgery team, our plastic surgery team, our critical care team, a lot of these doctors have had a presence and a training and a growth in Gurgaon. They have now helped us to establish the department in Noida. To that extent, there is a very close familiarity. This is not that is linked to limited to Gurgaon and Noida alone. This happens quite seamlessly across our network. Sure. Thank you so much. I will join back with you. Participants, please press star and one to ask a question. The next question comes from the line of Tushar Manudhane with Motilal Oswal Financial Services. Please go ahead. Thanks for the opportunity and congrats on a good set of numbers and the kind of scale-up that has been demonstrated at Noida hospital. Sir, ex Noida, if you could share what would have been the IPD growth on a year-on-year basis, in-patient volume growth. For the ex Noida, if you just look at our developing or what we now call as Cluster 2 hospitals, the IPD volume growth is around 27%. In a way, this volume growth has been very decent. You think, I mean, of course, can't determine the number of patients that would come in future, but the demand tailwind remains quite robust or this is more seasonality linked, and so the IP volume growth across hospitals, not just for Lucknow, Patna, but across our network. Now, what kind of IP volume growth one can sort of safely assume? Tushar, what's happened is across our Lucknow and Patna facility, as you would have seen for long periods of time, we've been seeing fairly high volume-driven growth. In fact, you would be aware, as we mentioned many times, we haven't really taken a tariff increase. A lot of the growth you're seeing in these units is all linked to volume. Now, we continue to see growth in Lucknow and Patna and upwards of 20% range. Also if you look at across the network, with the exception obviously of our Gurgaon facility, very high scale and almost 15 years of operations, we still see about 7%-10% volume growth in our Gurgaon facility. I think that we don't, at least in the short term, see any significant reduction in this kind of growth volumes. We still have beds to add in Lucknow and Patna. We still see, as far as those regions are concerned, the Bihar region, the Eastern UP region, huge unfulfilled potential. We have also seen, just interestingly, with the announcement of our hospital in Guwahati, a increased flow-through to our Gurgaon hospital from the northeast. As Medanta enters new and new territories and new geographies, we believe that we will continue to see an impact of that in our existing facilities as well. It serves to serve a greater population and also build the brand awareness in those areas. Got it, sir. As far as existing hospital, I mean, that was part of my question. The other part was the demand tailwind, any specific change that would have happened over last one to two years where the demand tailwinds have become much better or further stronger, if anything specifically you would like to highlight. The only thing. Sorry. Yeah Across the networks. Yeah. The only thing that I would say across all the regions which we operate in and across, I think probably true for most of the country, but definitely central and northern part of the country. We have seen a significant continued tailwind on demand with respect to the flight to quality care. We have seen a greater sense of awareness of health across the board. Obviously, with the affordability and rising income levels and the various opportunities to avail healthcare, this increases. Like we saw when we opened Lucknow and Patna, the minute you establish presence in these territories, it actually elevates the quality of care and elevates the awareness of the type of care that is available. We anticipate similar things happening when we open Guwahati. We are already seeing increased demand, as I mentioned. We anticipate that other cities which maybe did not have the ability to achieve or access high-quality care like Medanta provides will have that. Our belief is there will be a flight to quality. Our belief is that the demand will continue as access to healthcare improves for the country. Of course, as the income levels and affordability increase, we see this increasing as well. I think on a demand side, India from a healthcare point of view is very well-positioned. I think our real challenge is can we deliver the supply and more importantly, the high-quality, high ethics supply to meet that demand. Got it, sir. Just to cater to this demand, while the beds and the physical infrastructure is sort of setting up, we are adding doctors as well. Would you like to comment on any attrition rate which you have seen at a network level or any specific hospital level? We have seen very negligible to no attrition at any of our senior clinical levels across any of our hospitals. Of course, doctors do come and doctors go. I think in the last probably 6-18 months, barring of course the additions which we have done, I don't see any very significant changes in the attrition rates across the board. Of course, we do have high attrition rates in nursing. Junior doctors continue to be at a high attrition rate for the industry. But we haven't seen any significant shift or any of our senior doctors, so far at least, moving out from the system in any of these. Got it. That is commendable. Secondly, on retail pharmacy, maybe at a very small scale at this point of time, 13 pharmacies which are outside hospital network. Would you share the strategic aspect out here? How do we think about this as a segment? As we've always mentioned, we continue to look at the retail pharmacy outside the hospital and the retail labs as a extension of the care that we offer to the patients that touch the Medanta ecosystem. We will continue to maintain this at least for the foreseeable future. Our mission has been to ensure that we continue to provide the highest standard of services to all of our patients, and that does result in a demand of certain services beyond the walls of the hospital. So while we have a separate entity serving them from the retail pharmacy and the lab side, this also does extend to things like home care, things like clinics, access to the doctors beyond the walls of the bigger hospitals. We will continue to deliver that in the regions and areas where our existing hospitals are present. You will likely see increased expansion in our pharmacies and lab network in the same central and Northern India regions. We have yet not got any plans to extend to areas beyond where our hospital catchment is. Within this catchment, we will continue to scale it up. Like I said, again, not only pharmacy and labs, it will be part of the overall continuity of care portfolio. These will remain connected as one ecosystem within the Medanta group. If I could just extend to this, how many retail pharmacies do you think we'll add, let's say, over the next two years or two to three years? Next two to three? Years. Well, that I don't know. I think that we are currently operating about 13 retail pharmacies. We have some of them also running in our clinics. We will likely scale up our retail pharmacies in some of the markets where we have seen very high demand from our patients, like UP and Bihar. There is a very significant shortage of high-quality and high-credibility medicines in these territories. We will scale it up. I don't think you will see our pharmacies, Tushar, go from a number of 20+ 100 or 200 or anything like that in the next year. We will continue to increase the rate of growth. If we were adding 10 pharmacies a quarter, maybe it will become 15 or 20. I don't think that in the next, I would say, maybe four to six quarters, you will see any very rapid exponential or multiplier growth. You will see steady growth across the network. Got it. Just last on Noida side, the number of beds have increased, but as I could see in the slides, the OTs or ICUs have remained same, even if I think about beds increasing from 320- 433. Am I missing something in terms of interpretation? Yeah, no. Unlike some of our other facilities where we had a different physical structure of multiple towers, in Noida, as we had mentioned when we started out this journey, it's a single tower hospital. What you're seeing in terms of the bed additions are really just the additional floors opening up. The operating rooms because of the nature in how we build them out was all operationalized and commissioned on day one. It is unlikely you will see in the short term any incremental operating room capacity increase in Noida hospital because as on date, this is what is our installed base. However, you may see increases as the demand improves on increasing procedure areas which are non-OT, like cath labs, like radiation oncology, et cetera. That will still take some time. No capex is planned in the next couple of quarters against that. As and when the need is there, we will continue to add that. Unlikely to see any OT increase. Got it, sir. Thanks a lot and all the best. Thank you. The next question comes from the line of Vivek with Emkay Global Financial Services. Please go ahead. Thank you for the opportunity. Congratulations to the team on a good set of numbers. I had three questions. Firstly, just wanted to understand in terms of the growth in Gurgaon unit. Given how quickly we are ramping up the developing units and within that the growth that we have witnessed, I'm assuming that growth is sort of equivalent to how Lucknow has also grown? My question was basically to understand why can't we replicate the level of growth that we are doing in Lucknow in Gurgaon. That's the first question. Look, I think we have to be respectful of the realities that Gurgaon is a 15-year-old hospital of 1,500 beds, which is running quite full versus a five to six-year-old hospital which is at about 750 beds. Structurally and fundamentally, these are different. Secondly, you have to understand the entire geographic and patient demographic situation of Eastern U.P. You are talking about a population base in Eastern U.P., which is maybe 100 million people plus versus, say, NCR or geographic base of Gurgaon plus Delhi, plus maybe parts of Haryana, which will be much, much smaller. I don't think that it is logical to compare any of these two units, both in terms of time scale and the basics of where they operate out of. That being said, I think it's also fair to say that Lucknow historically over the last five, six years of its operations, has performed at growth rates, which frankly speaking have been just exceptional and not seen in many hospitals in the country ever. It is not easy to say why is that not there all the time everywhere. It has been a phenomenal performance in Lucknow. We are very happy about that, but it's a little unrealistic also to claim that. We've always maintained that that is not normal. That being said, a 15-year-old hospital, which is growing by double digits in volume after having such a high scale of 1,400, 1,500 beds, I think is also a feat that you do not see that frequently. In fact, if you look back over the last four or five years, since we've been listed at least you can say two, three years, I think we are the only major listed chain that has been growing consistently in double digits on volume as opposed to on tariff or revenue or realizations. This is in line with our philosophy, help touch more and more lives, deliver as much as you can with as little burden to the patient population. We are very happy with the way all the units have been growing. Each one of them does require to be looked at independently. It's not logical to compare them just on a single dimension. Got it. Thank you for the detailed answer. Secondly, with respect to your revised expansion plan for Guwahati. Earlier we had 400 beds, and we had allocated a CapEx for those 400 beds of around INR 500 crores, right? We have now revised, basically for the incremental 250 beds, we have increased our CapEx also by approximately INR 500 crores. Could you explain the reason behind the higher CapEx per bed, basically for the incremental beds that have come to the fore now for Guwahati? Yeah. Actually, as we had mentioned once or twice in the past, beds alone is not the way in which we think about the build-out of the hospital. I'll give you some color on what has happened. With the changes in the National Building Code and the relevant bylaws which apply to us in Assam and Guwahati, we have been able to actually significantly increase our square footage of the building, which we are making. The main difference is that the floor plate, which was somewhere around 30,000 sq ft or 40,000 sq ft, now has almost doubled to about 60,000 sq ft. What that means for us more than beds is it gives us an opportunity to significantly scale up our procedural capacity. We have actually doubled the number of operating rooms that we were planning. I think it was planned somewhere around 13, 14, and that has now gone almost to 28, 30 operating rooms. As you are aware, Medanta operates our facilities on a very high-end procedure orientation. We have almost doubled our operating rooms, doubled our cath labs, doubled our LINACs and our bunkers for radiation oncology. More than absolute number of beds, the space is being taken up in increased procedure areas in line with the kind of work which we do. The CapEx which you see is not linked only to a bed number, but it would be linked to the complete procedure area and our square footage going up from about INR 6.5 lakhs to about almost INR 9.8 lakhs now. Got it. Just to clarify, this incremental CapEx doesn't include any additional area or land that we have had to purchase, right? This is in the- No Existing. What happened is that with the changing rules, we have been able to get additional FSI at no cost, additional ground coverage, and so on and so forth. Also the height restrictions, which were there in the National Building Code before this one, that has been increased to about 60 m. The ability to build more on the same plot of land has increased, so to speak. Got it. One final thing in terms of CGHS. Have we seen the impact of CGHS rate hike that were announced in October come into full flow from this quarter? If you could quantify the benefit as well to the revenue and the margins. Yeah. I think the benefit is fully captured in because the hike was announced in October, and we are talking about April to June. Definitely it is fully baked into this quarter. We don't capture or report out the benefit just because of the CGHS rate hike. Obviously, this hike is coming from, I think last time it was 2017. We are sitting in 2026, it's a long overdue hike. There has been some positive impacts of it. I think on the larger overall P&L of the company or overall revenue of the company, I don't think that this is moving it by several hundred basis points or anything like that. Of course, it's beneficial. That was share of CGHS, it wasn't all that. As Yogesh is saying, in Medanta, our scheme CGHS business is not very high. I think somewhere in the 10%, 12% range. For us, it's not moving the needle on the total revenue. Of course, for whatever it is, it's beneficial. Our growth is mainly led by the volumes rather than the tariff, basically. Got it. That was it from my end. Thank you so much. The next question comes from the line of Raman K.V. with Sequent Investments. Please go ahead. Hi, sir. Can you hear me? Yes, we can hear you. Sir, I just have two questions. One is with respect to Cluster 1, which grew around 10%. When we compare it with Cluster 2, there is a slowdown in the growth. Is it because of the capacity constraint? Are we planning to have any brownfield expansion in the Cluster 1 hospitals? Okay, I'm not sure I can see where you're referencing the slowdown. Our Cluster 1 has grown by approximately 10% on a revenue basis and I think higher on a volume basis. Cluster 1 includes Gurgaon, Indore, and Ranchi. Sir, when I say- Indore is- Sir, when I say slowdown, I was comparing it with the Cluster 2 hospital, which has grown 30%, more than 30%. So- When we look at it on a consolidated basis, the consolidated revenue grew by 20%. Yeah. In comparison to that, I was talking. Yeah. More than slowdown, you mean relative growth between the two clusters. Let me revert to the answer I had given to a previous question around the fact that these are not necessarily comparable. Before we do that, let me just answer your point on whether there will be any brownfield expansion in these clusters. Just coming back to that. First, Cluster 1, Indore and Ranchi. We have added in over the course of the last few months, some beds in our Ranchi facility. We added 100-bed facility, I think it was some point in the last financial year. I forget the exact date now. And we have a 80-bed facility which we had acquired, which should come on board towards the end of Q2, maybe early Q3 in Indore. Both of these facilities will help us to provide the missing services around cancer, which we did not have in Indore and Ranchi. We do see some brownfield bed capacity coming on board. Our Ranchi facility is already functional, but it is scaling up as well. You will see some capacity benefits in both Ranchi and Indore. In Gurgaon, I think I had mentioned in our last earnings call, more than beds, we are adding procedural capacity. We have activated additional operating rooms in Gurgaon. We will probably in the coming quarter activate two more operating rooms. That should take our total operating room capacity to almost 44, 45 operating rooms in this facility. We will also be commissioning, hopefully in this coming quarter, which is Q2, additional cath labs. We may add two to three cath labs, so we will find additional procedural capacity in Gurgaon as well. Like I was mentioning in response to another question. The increase for us is not always linked to beds because as you can see, we are fairly efficient in our bed turnover with a low length of stay. We would like to become more efficient, but procedural capacity increase could be there. I think the way I would like to answer your question on brownfield growth in Cluster 1 is it will be a combination of beds and procedural capacity in all the three units, right? That being said, obviously, we are sitting on a huge base. You are talking about a patient volume which is very, very high in terms of inpatient care processing over 30,000, 35,000 patients a quarter. Obviously that will grow at a slightly different rate compared to our Cluster 2. Even if I take out Noida, you see a growth in Lucknow and Patna on a volume basis of about 27%, I think I had mentioned in response to an earlier question, and that also continues to grow quite well. We are incidentally also adding procedural capacity both in Lucknow and Patna without necessary addition of bed group. I think I'd mentioned again in my last quarter earnings call that we are adding operating rooms in Lucknow, we are adding operating rooms in Patna, and we are also adding bed capacity in both of these units. You will see beyond, of course, Noida scale-up, you will see bed capacity and procedural addition across almost every one of our units. Okay. Understood, sir. Thank you for the clarification. Sir, my second question is on the margin front. Margin from Cluster 2 hospitals, except Noida, is far greater than margin from Cluster 1 hospital. Can we assume this Cluster 2 hospitals to have 30% margins for the near future? Also once the utilization ramps up with respect to Noida facility, will that also be a 30% margin business? You know, we don't give margin guidance, and I would not like to hazard a guess on what the margin would be in the future in Patna or Noida. I can, however, just clarify a couple of points for you. The first and important point is that our complete overhead cost base of our complete group costs, corporate costs, et cetera, are all fully loaded in our Gurgaon facility, so in Cluster 1. To that extent it may not always be comparable because there is a slightly inflated costs in Cluster 1 and slightly deflated costs in Cluster 2 to that effect, right? The second thing obviously is that despite slightly lower RPops and lower utilizations, obviously we don't have as much legacy cost in our newer units as we do, say, maybe in our older units. There are some benefits to that. The third thing is that obviously as and when you scale up hospitals, you try to become more and more efficient. There are some differences in the cost structure depending on where you are exactly operating, depending on the type of clinical talent that you have. Of course, Gurgaon being a major facility has a greater number of senior doctors. There are all these various differences in each of the units. Beyond comparing the margin profile across units, what I can say is that we do see operating leverage kicking in Noida, so that should help with margin profile. We don't see any very significant structural difference in the cost base on any unit. Therefore, as you find greater realization moving towards higher procedural elements, to the extent that there are tariff revisions or benefits around that, these all should be margin accretive. Of course, there may be situations which may be margin dilutive also, but structurally, we don't see any very significant shift in our cost base. Hopefully it should at least remain stable or continue to grow. Understood. Sir, I just want to clarify. My question was mainly on the front that the margin difference between Cluster 1 and Cluster 2, it's only because of the corporate overruns, or is it because in Cluster 2 we are doing some specialized treatments which are usually a high-margin business? No, I don't think that there's anything which is very different, which we are doing in Cluster 2, which is not being done in Cluster 1. Obviously there are certain greater operating efficiencies given that they are slightly newer units. Just to give you a very simple example, in a newer unit, you may not have annual maintenance contracts, repairs and maintenance types of expenses because the equipment may still be under warranty. Whereas in an older unit, you would be having a higher level of R&M costs. In an older unit, you may have a slightly less efficient manpower structure because of legacy costs. In a newer unit, you may have started out with a more efficient structure. These are all operational things which keep getting optimized across the network, but no structural difference or no very great difference in the type of work which we're doing. Understood, sir. Thank you. Thank you so much. Thank you. Thank you. Ladies and gentlemen, we will take that as the last question for today. I would now like to hand the conference over to the management for the closing remarks. Thank you everyone for your questions today and for joining us. My apologies once again for the technical glitch in the middle of the call. I hope that did not create too much disturbance for you. Just to come back to what we were saying, as we look at our company, as we look at our organization, we are very happy with our performance thus far. As we scale, we will continue to focus on what has always defined us, which is our exceptional clinical depth and talent, our operating discipline, and our commitment to delivering the highest quality outcomes that matter to our patients. Please do feel free to reach out to our Investor Relations team in case any of your questions remain unanswered, and we look forward to meeting you again soon. Thank you very much. Thank you, sir. Ladies and gentlemen, on behalf of JM Financial Institutional Securities, that concludes this conference call. Thank you for joining us, and you may now disconnect your line.